Clinical Research Directory
Browse clinical research sites, groups, and studies.
Single-Dose HPV Vaccination for the Prevention of Cervical Cancer in Young Adult Women in Costa Rica, The PRISMA ESCUDDO Trial
Sponsor: National Cancer Institute (NCI)
Summary
This phase IV trial tests whether a single dose of the human papillomavirus (HPV) vaccine works in preventing cervical cancer in young women in Costa Rica. Human papilloma viruses, called HPV, are a group of viruses that very frequently cause infection in both men and women, mainly in the genital organs. There are many types of HPV, and some can cause cancer. The World Health Organization recommends a two-dose schedule for adolescents 9-14 and three doses for individuals 15 years old or older. This study examines whether a single dose of HPV vaccine can reduce the frequency with which women between ages 18-30 become infected with HPV.
Official title: Single-Dose HPV Vaccination Among Young Adult Women in Costa Rica: the PRISMA-ESCUDDO Trial (PRevencIón Del Cáncer Cervical Con Una Sola Dosis de Vacuna Contra VPH en Mujeres Adultas Jóvenes)
Key Details
Gender
FEMALE
Age Range
18 Years - 30 Years
Study Type
INTERVENTIONAL
Enrollment
5000
Start Date
2022-03-01
Completion Date
2026-05-31
Last Updated
2026-04-09
Healthy Volunteers
Yes
Interventions
Diphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis Vaccine Adsorbed
Given IM
Questionnaire Administration
Ancillary studies
Recombinant Human Papillomavirus Bivalent Vaccine
Given IM
Recombinant Human Papillomavirus Nonavalent Vaccine
Given IM
Locations (1)
Agencia Costarricense de Investigaciones Biomédicas (ACIB)
Liberia, Guanacaste Province, Costa Rica